Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients
For cardiac transplant (CTx) recipients, the recommended everolimus (EVL) dose is 0.75 mg bid or 1.5 mg bid and the target trough blood level is 3–8 μg/L. We studied a cohort of 56 CTx patients with chronic kidney disease receiving 0.75 mg bid EVL to maintain blood levels of 5–8 ug/L (designated RD...
Saved in:
| Main Authors: | Uwe Fuchs, Armin Zittermann, Uwe Schulz, Jan F. Gummert |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Journal of Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2012/976921 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term use of everolimus as a component of immunosuppressive therapy in liver transplant recipients
by: M. Sh Khubutia, et al.
Published: (2016-01-01) -
Pharmacoeconomic analysis of everolimus immunosuppressive therapy for <i>de novo</i> kidney transplant recipients in Russia
by: N. A. Avxentyev, et al.
Published: (2019-05-01) -
EVEROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS
by: E. I. Prokopenko
Published: (2010-06-01) -
Analysis of early use of everolimus with low-dose calcineurin inhibitors in kidney transplant recipient
by: I. G. Kim, et al.
Published: (2019-10-01) -
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
by: Saygın Yıldırım, et al.
Published: (2023-06-01)